Aluminium hydroxide

About: Aluminium hydroxide is a research topic. Over the lifetime, 2043 publications have been published within this topic receiving 22032 citations. The topic is also known as: Al(OH)3 & Amphojel.

Alkali-free liquid accelerating agent and preparation method thereof

Abstract: The invention belongs to the technical field of tunnel construction, and relates to an alkali-free liquid accelerating agent for tunnel wet jet concrete and a preparation method thereof. The alkali-free liquid accelerating agent is characterized in that aluminium sulphate is adopted to serve as a main accelerating component; aluminium is added to an aluminium sulphate solution to be polymerized in a form of aluminium fluoride; aluminium ions are introduced to the greatest extent so as to reduce other ion introduction; and the accelerating effect is ensured. The alkali-free liquid acceleratingagent comprises the following components in percentage by mass: 30-55% of aluminium sulphate, 5-15% of aluminium hydroxide, 10-30% of hydrofluoric acid, 0.5-5% of water glass, 0-0.2% of stabilizing agent, and the balance of water. For jetting concrete, the alkali-free liquid accelerating agent disclosed by the invention has the positive effects that: ordinary cement can be initially solidified within 2 min in lower doping quantity and finally solidified within 4 min; the 1d strength of cement plaster can achieve above 15 MPa; the 28d compressive strength ratio is more than 100%; and the alkali-free liquid accelerating agent has good adaptability to different types of cements.

Value of serum aluminium monitoring in dialysis patients: a multicentre study.

Abstract: The clinical relevance of regular serum aluminium monitoring in dialysis patients was investigated in a multicentre study by 6-monthly determination of the serum aluminium during 4 consecutive years. In a group totalling 1193 patients, a striking decrease of mean serum aluminium was observed the last 2 years of the study. This phenomenon was accompanied by a substantial reduction of the prescribed dose of aluminium hydroxide (Al(OH)3) and its partial replacement by calcium carbonate (CaCO3) and/or magnesium hydroxide (Mg(OH)2). Under this policy serum phosphate control remained satisfactory. In all the centres, water treatment was found to be adequate, yielding dialysate aluminium around 2 micrograms/l. Dialysis patients with clinically overt liver disease showed a significantly greater median serum aluminium concentration than that observed in a control dialysis population. Compared to the latter group, the median serum aluminium concentration of dialysis patients with diabetes mellitus did not differ significantly. Results further indicated that patients with biopsy-proven osteomalacia presented a significantly greater median serum aluminium compared to that of patients without osteomalacia. We demonstrated that a serum aluminium of 60 micrograms/l provides a relatively sensitive (82%) and specific (86%) index for the detection of aluminium-related bone disease (ARBD). Provided the aluminium determinations are performed by a qualified laboratory, serum monitoring in dialysis patients (a) allows the safer use of aluminium-containing phosphate binders, and (b) is of value in the diagnosis of overload/toxicity.